Human Immunology Biosciences (HI-Bio), a clinical-stage biotechnology company, announced on Thursday that it has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for its felzartamab.
The product is intended to treat antibody-mediated rejection (AMR) in kidney transplant recipients.
Orphan Drug Designation allows the company for certain development incentives, including tax credits for qualified clinical trials, exemption of FDA application fees and up to seven-year market exclusivity upon regulatory approval.
The product is an investigational therapeutic human monoclonal antibody aimed at CD38, a protein expressed on mature plasma cells.
Pierre Fabre Pharmaceuticals reports FDA acceptance and Priority Review of Tabelecleucel BLA
Bavarian Nordic's chikungunya vaccine receives validation from EMA for accelerated review
Atara Biotherapeutics gains FDA Priority Review for tabelecleucel
Hyperfine secures FDA clearance for faster brain imaging software
Silo Pharma agrees Alzheimer's drug licence
Kyverna's KYV-101 granted FDA Regenerative Medicine Advanced Therapy designation
Camurus reports positive Phase 3 ACROINNOVA 2 results
Acurx Pharmaceuticals presents positive Ibezapolstat Phase 2 clinical trial results for CDI